Oral composition

Abstract

The present invention provides an oral composition that quickly and effectively imparts an effect of inhibiting hyperesthesia. The oral composition comprises: (A) a polyacrylate having a weight average molecular weight of 1,000 to 20,000, and (B) at least one selected from potassium nitrate, potassium acetate, potassium chloride, aluminum lactate, and aluminum chloride. The oral composition further comprises (C) an alkyl sulfate.

Description

Technical Field

[0001] The present invention relates to an oral composition which rapidly and effectively imparts a hypersensitivity suppressing effect. Background Art

[0002] Hyperesthesia refers to transient, extremely unpleasant pain caused by thermal, chemical, and physical external stimuli to exposed dentin. Therefore, in order to alleviate this symptom, potassium salts such as potassium nitrate are often used as nerve paralysis components to act on exposed nerves. In addition, aluminum salts such as aluminum lactate are used as dentin tubule blocking components that act in another pathway such as blocking dentin tubules and are mixed into oral compositions.

[0003] However, although potassium salts such as potassium nitrate have a relatively quick-acting effect on the inhibition of hypersensitivity, it is not sufficient and the effect is difficult to sustain. Aluminum salts such as aluminum lactate have a non-quick-acting effect on the inhibition of hypersensitivity, and these effects are limited. Moreover, when these substances are mixed in an oral composition, they are easily affected by other mixed components. In particular, the more potassium salts are used, the more they affect the basic characteristic, i.e., foaming, and the oral composition cannot be spread throughout the oral cavity, making it difficult to fully demonstrate the hypersensitivity inhibition effect. Therefore, in an oral composition, it is a subject to improve the allergy inhibition effect produced by potassium salts and the like and make it further quick and effective.

[0004] Patent document 1 (Japanese Patent No. 5790455) proposes that when a specific water-soluble polymer is mixed with a dentifrice composition mixed with potassium nitrate or aluminum lactate and sodium lauryl sulfate, foaming is ensured and the hypersensitivity suppression effect is achieved, but the hypersensitivity suppression effect is poor in the evaluation after 4 weeks of use. Patent document 2 (Japanese Patent No. 5924002) proposes to control the concentration ratio of potassium ions and sodium ions. In addition, when amphoteric surfactants and specific polymer substances are mixed, the hypersensitivity suppression effect can be exerted at a high ratio. Patent document 3 (Japanese Patent Publication No. 2017-141178) proposes that when α-olefin sulfonic acid and sucralose are mixed with a dentifrice composition mixed with potassium nitrate or aluminum lactate, foaming performance and hypersensitivity suppression effect can be ensured.

[0005] Prior art literature

[0006] Patent Literature

[0007] Patent Document 1: Japanese Patent No. 5790455

[0008] Patent Document 2: Japanese Patent No. 5924002

[0009] Patent Document 3: Japanese Patent Application Publication No. 2017-141178

[0010] Patent Document 4: International Publication No. 2019 / 107335

[0011] Patent Document 5: International Publication No. 2019 / 107340

[0012] Patent Document 6: International Publication No. 2019 / 107338 Summary of the invention

[0013] Problem that the invention aims to solve

[0014] The present invention has been made in view of the above circumstances, and an object of the present invention is to provide an oral composition that rapidly and effectively imparts an excellent hypersensitivity suppressing effect.

[0015] Means to solve problems

[0016] As a result of intensive research to achieve the above-mentioned object, the present inventors have found that when a polyacrylic acid salt having a weight average molecular weight of not more than a specific value is used in combination with a potassium salt or an aluminum salt having an effect of suppressing hyperesthesia and mixed in an oral composition, the rapidity of the hyperesthesia suppressing effect is improved, and a high hyperesthesia suppressing effect can be rapidly and significantly imparted from immediately after use. That is, the present inventors have found an oral composition that rapidly and effectively imparts an excellent hyperesthesia suppressing effect and has a good smell, and have completed the present invention, wherein the oral composition is mixed with (A) a polyacrylic acid salt having a weight average molecular weight of not less than 1,000 and not more than 20,000 and (B) at least one selected from potassium nitrate, potassium acetate, potassium chloride, aluminum lactate, and aluminum chloride.

[0017] In the present invention, the polyacrylic acid salt of a specific molecular weight (A) and the component (B) in the oral composition specifically interact with each other to preferentially form a complex of the two. The improvement of the retention of the component (B) in the oral cavity is an important factor, and the rapidity of the hyperesthesia suppressing effect of the component (B) can be significantly improved. Potassium salt has a nerve paralysis effect, and aluminum salt has a dentinal tubule sealing effect, and the hyperesthesia suppressing effect is exerted in different pathways. However, even with such different mechanisms of action, in the present invention, the hyperesthesia suppressing effect of the component (B) is enhanced by the component (A), and a high hyperesthesia suppressing effect can be exerted quickly, and the effect can be sustained from the beginning of use.

[0018] When the component (B), especially a potassium salt containing potassium ions, is mixed in combination with sodium lauryl sulfate, which is an anionic surfactant widely used in oral compositions to ensure foaming, there are problems such as a decrease in the nerve paralysis effect due to a decrease in the free potassium ion concentration or precipitation of poorly soluble potassium lauryl sulfate, which leads to a decrease in the foaming amount. However, in the present invention, by using the components (A) and (B) in combination and further combining and mixing with the component (C), the above problems do not occur, and sufficient foaming can be ensured to achieve an appropriate foaming amount, thereby exerting the above-mentioned excellent hyperesthesia suppressing effect.

[0019] As can be seen from the comparative examples described below, if the (A) component is not mixed, the hyperesthesia suppressing effect (the rapidity of the effect) is low, and even if a polyacrylate with an inappropriate molecular weight is added, the hyperesthesia suppressing effect is poor (Comparative Examples 1 to 9), and the effect of the present invention is not obtained.

[0020] Patent Documents 1 to 3 describe a dentifrice composition having an effect of suppressing hypersensitivity, wherein a water-soluble polymer, a sodium supply source, and sodium polyacrylate as a binder are mixed, but the molecular weight thereof is not mentioned. In oral compositions, a cross-linked polyacrylic acid or a salt thereof having a weight average molecular weight of 100,000 or more, usually about 300,000, is generally used as a binder.

[0021] In addition, Patent Documents 4 to 6 (International Publication No. 2019 / 107335, International Publication No. 2019 / 107340, International Publication No. 2019 / 107338) record the inhibition of oral biofilm formation and the improvement of its own stimulation caused by polyacrylic acid with a weight average molecular weight of 20,000 or less in the oral composition, but do not focus on inhibiting hypersensitivity. The present invention improves the hypersensitivity inhibitory effect of component (B) by component (A), especially improves its rapid effect, and through the combined use of components (A) and (B), it has a particularly significant effect that cannot be achieved when using polyacrylate with a weight average molecular weight greater than 20,000 instead of component (A).

[0022] Therefore, the present invention provides the following oral composition.

[0023] [1]

[0024] An oral composition comprising:

[0025] (A) a polyacrylic acid salt having a weight average molecular weight of 1,000 or more and 20,000 or less, and

[0026] (B) at least one selected from the group consisting of potassium nitrate, potassium acetate, potassium chloride, aluminum lactate and aluminum chloride.

[0027] [2]

[0028] The oral composition according to [1], wherein the component (B) is selected from potassium nitrate and aluminum lactate.

[0029] 〔3〕

[0030] The oral composition according to [1] or [2], wherein the content of the component (A) is 0.005 to 2.5% by mass, and the content of the component (B) is 1 to 10% by mass.

[0031] [4]

[0032] The oral composition according to any one of [1] to [3], wherein (A) / (B) is 0.001 to 0.5 in terms of mass ratio.

[0033] 〔5〕

[0034] The oral composition according to any one of [1] to [4], further comprising (C) an alkyl sulfate.

[0035] [6]

[0036] The oral composition according to [5], wherein the (C) alkyl sulfate is at least one selected from sodium lauryl sulfate and sodium myristyl sulfate.

[0037] 〔7〕

[0038] The oral composition according to [5] or [6], wherein the content of the component (C) is 0.1 to 2% by mass.

[0039] [8]

[0040] The oral composition according to any one of [5] to [7], wherein (B) / (C) is 1 to 50 in mass ratio.

[0041] 〔9〕

[0042] The oral composition according to any one of [1] to [8], wherein the oral composition is a dentifrice composition.

[0043] 〔10〕

[0044] The oral composition according to any one of [1] to [9], which is for suppressing hyperesthesia.

[0045] Effects of the Invention

[0046] According to the present invention, a composition for oral cavity that quickly and effectively imparts an excellent hyperesthesia suppressing effect can be provided. The composition for oral cavity of the present invention has an excellent hyperesthesia suppressing effect, can ensure good and appropriate foaming, and has a good smell, and is effective as a hyperesthesia suppressing agent for preventing or suppressing hyperesthesia. DETAILED DESCRIPTION

[0047] The present invention is described in more detail below. The oral composition of the present invention contains (A) a polyacrylate having a weight average molecular weight of 1,000 to 20,000 and (B) at least one selected from potassium nitrate, potassium acetate, potassium chloride, aluminum lactate and aluminum chloride, and preferably further contains (C) an alkyl sulfate.

[0048] The polyacrylate (A) having a weight average molecular weight of 1,000 to 20,000 serves to enhance the hypersensitivity suppressing effect of the component (B), in particular, to enhance its rapid effect. In addition, it also helps to ensure foaming. The component (A) reduces the metallic taste and other odors from the component (B), further masks the irritation caused by the component (C) and reduces the odor associated with the irritation, and also serves to ensure a good smell during use.

[0049] In order to improve the hyperesthesia suppressing effect caused by the (B) component, improve its rapid effect and the feeling of use, the weight average molecular weight (Mw) of the polyacrylate of the (A) component is preferably 1,000 or more and 20,000 or less, particularly 6,000 or more and 10,000 or less, and particularly 6,000 or more and 9,000 or less. When the weight average molecular weight of the polyacrylate is greater than 20,000, the effect of improving the hyperesthesia suppressing effect is poor.

[0050] The weight average molecular weight is measured by GPC (gel permeation chromatography) according to the method and measurement conditions described in Japanese Patent No. 5740859. The details are as follows (the same applies hereinafter).

[0051] Method for determining weight average molecular weight;

[0052] The weight average molecular weight is a value measured using a gel permeation chromatography / multi-angle laser light scattering detector (GPC-MALLS), and the conditions are as follows.

[0053] Mobile phase: 0.3M NaClO4

[0054] NaN3 aqueous solution column: TSKgelα-M 2 pieces

[0055] Pre-column: TSK guard column α

[0056] Standard substance: polyethylene glycol

[0057] The polyacrylic acid salt of the component (A) is preferably a linear polyacrylic acid salt from the viewpoint of enhancing the hyperesthesia suppressing effect, particularly enhancing its rapid effect.

[0058] The salt is preferably a monovalent salt, more preferably an alkali metal salt or an ammonium salt, more preferably an alkali metal salt, and examples thereof include a sodium salt and a potassium salt, and particularly preferably a sodium salt.

[0059] As such a polyacrylate, commercially available products sold by Polyscience Co., Ltd. or Toagosei Co., Ltd. can be used.

[0060] As specific commercial products, sodium polyacrylate (Mw: 1,000): linear, manufactured by Polyscience; sodium polyacrylate (Mw: 6,000): linear, manufactured by Toagosei Co., Ltd., JURYMER AC-10NP, JURYMER AC-10NPD, Aron T-50; sodium polyacrylate (Mw: 8,000): linear, manufactured by Polyscience; sodium polyacrylate (Mw: 9,000): linear, manufactured by Polyscience; sodium polyacrylate (Mw: 20,000): linear, manufactured by Toagosei Co., Ltd.; Aron A-20UN, etc. can be used.

[0061] The mixing amount of component (A) is preferably 0.005 to 2.5% (mass %, the same below) of the whole composition, more preferably 0.01 to 2%, and further preferably 0.01 to 1%. When it is 0.005% or more, the rapidity of the hypersensitivity suppressing effect can be sufficiently improved to prepare an excellent composition. In addition, the odor from component (B) can also be suppressed. When mixed too much, there is a tendency for the rapidity of the hypersensitivity suppressing effect to decrease, but when it is less than 2.5%, a sufficient hypersensitivity suppressing effect is ensured. In addition, good foaming can also be maintained.

[0062] The component (B) is one or more selected from potassium nitrate, potassium acetate, potassium chloride, aluminum lactate and aluminum chloride, and they are desensitizing agents and exert an effect of suppressing hyperesthesia.

[0063] Potassium salts such as potassium nitrate, potassium acetate or potassium chloride have a neuroparalytic effect on dentinal tubules, and aluminum salts such as aluminum lactate or aluminum chloride have a dentinal tubule sealing effect.

[0064] As the component (B), the above-mentioned potassium salts and / or aluminum salts can be used, and among them, potassium nitrate and / or aluminum lactate are particularly preferred from the viewpoint of the hyperesthesia suppressing effect.

[0065] The blending amount of component (B) is preferably 1 to 10%, more preferably 2 to 8%, of the entire composition. When the blending amount is 1% or more, the hyperesthesia suppressing effect is sufficiently excellent, and when it is 10% or less, sufficient foaming is ensured.

[0066] From the viewpoint of the hyperesthesia suppressing effect and ensuring foaming, the blending amount of the component (B), particularly the potassium salt, may be 5% or more (particularly 5 to 8%), and further may be 6% or more of the entire composition.

[0067] (A) / (B), which represents the ratio of the amount of the component (A) to the amount of the component (B), is preferably 0.001 to 0.5, more preferably 0.002 to 0.4, further preferably 0.005 to 0.3, and particularly preferably 0.01 to 0.2 in terms of mass ratio. When the mass ratio of (A) / (B) is within the above range, the hyperesthesia suppressing effect is more excellent, and the odor is suppressed, and the smell is also good.

[0068] In order to ensure foaming, it is preferred to further mix (C) an alkyl sulfate with the oral composition of the present invention.

[0069] (C) The alkyl sulfate is preferably sodium lauryl sulfate or sodium myristyl sulfate, and particularly preferably sodium lauryl sulfate.

[0070] From the perspective of the foaming and hyperesthesia suppressing effects, the blending amount of the (C) component is preferably 0.1 to 2% of the total composition, more preferably 0.1 to 1.8%, further preferably 0.6 to 1.5%, and may be 1.1% or more. When the blending amount is 0.1% or more, the foaming amount can be sufficiently ensured. When blending too much, the hyperesthesia suppressing effect may be affected, but when the blending amount is 2% or less, the hyperesthesia suppressing effect is sufficiently excellent.

[0071] (B) / (C), which represents the ratio of the amount of the component (B) to the amount of the component (C), is preferably 1 to 50, more preferably 1 to 20, further preferably 1 to 10, and particularly preferably 1 to 6, in terms of mass ratio. When the mass ratio of (B) / (C) is within the above range, foaming becomes further improved, sufficient foaming amount can be ensured, and a composition with a more excellent hyperesthesia suppressing effect can be obtained. In addition, odor is suppressed, and the feeling during use is also good.

[0072] The oral composition of the present invention is particularly preferably used as a dentifrice composition such as toothpaste, and is prepared by a common method. In addition, in addition to the above-mentioned components, other known components can also be mixed as needed within the scope of not damaging the effect of the present invention. For example, abrasives, wetting agents, binders, surfactants can be mixed in toothpaste, and sweeteners, colorants, preservatives, spices, active ingredients, etc. can be further mixed as needed. In addition, within the scope of not damaging the effect of the present invention, the mixing amount can be a common amount.

[0073] The oral composition of the present invention may contain other optional components that are generally used as necessary depending on the dosage form.

[0074] Examples of the abrasive include silica-based abrasives such as silicic anhydride, precipitated silica, aluminosilicate, and zirconium silicate; calcium phosphate-based compounds such as dicalcium phosphate dihydrate or its anhydrous form; and calcium carbonate and synthetic resin-based abrasives. The mixing amount of the abrasive is usually 2 to 50%, particularly 10 to 40%.

[0075] Examples of the wetting agent include sugar alcohols such as sorbitol and xylitol, and polyols such as glycerol and propylene glycol. The blending amount of the wetting agent is usually 5 to 50%, particularly 20 to 45%.

[0076] The binder may be mixed with an organic or inorganic binder. Specifically, organic binders such as sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose and other cellulose derivatives, alginic acid derivatives, xanthan gum and other gums, carrageenan, polyvinyl alcohol, sodium polyacrylate, and inorganic binders such as gelling (thickening) silica and gelling (thickening) aluminosilicate may be mentioned. The mixing amount of the binder is usually 0.1 to 10%, especially 0.1 to 5%.

[0077] The surfactant may be mixed with anionic surfactants, nonionic surfactants, cationic surfactants, and amphoteric surfactants other than the component (C).

[0078] Examples of the optional anionic surfactant include acyl sarcosinates, acyl taurates, and acyl amino acid salts.

[0079] Examples of the nonionic surfactant include sugar fatty acid esters such as sucrose fatty acid esters, sugar alcohol fatty acid esters, sorbitan fatty acid esters, glycerol fatty acid esters, polyglycerol fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene fatty acid esters such as polyoxyethylene hydrogenated castor oil, polyoxyethylene higher alcohol ethers, and fatty acid alkanolamides.

[0080] Cationic surfactants include quaternary ammonium salts such as alkyl ammonium type and alkyl benzyl ammonium salts.

[0081] Examples of the amphoteric surfactant include betaine-type surfactants such as alkyl betaine and fatty acid amide propyl betaine, and imidazolinium betaine-type surfactants such as alkyl imidazolinium betaine and 2-alkyl-N-carboxymethyl-N-hydroxyethyl imidazolinium betaine.

[0082] The blending amount of the surfactant is usually 0.1 to 10%, particularly 0.5 to 5%.

[0083] Examples of the colorant include Blue No. 1, Yellow No. 4, and titanium dioxide.

[0084] Examples of sweeteners include saccharin sodium.

[0085] Preservatives include hydroxybenzoic acid esters such as methyl parahydroxybenzoate, benzoic acid or its salts, and the like.

[0086] Spices can be used in combination with peppermint oil, spearmint oil, anise oil, eucalyptus oil, wintergreen oil, cinnamon oil, clove oil, thyme oil, sage oil, lemon oil, orange oil, mint oil, cardamom oil, coriander oil, tangerine oil, pear berry oil, lavender oil, rosemary oil, laurel oil, chamomile oil, fennel oil, marjoram oil, bay leaf oil, citronella oil, oregano oil, pine needle oil, neroli oil, rose oil, jasmine Natural flavors such as oil, grapefruit oil, sweet grapefruit oil (suiti oil), yuzu oil, iris extract, peppermint essential oil, rose essential oil, orange blossom, and processed flavors (removal of the fore-fraction, removal of the after-fraction, fractionation, liquid-liquid extraction, refining, powdered flavoring, etc.) of these natural flavors, as well as menthol, carvone, anethole, eucalyptol, methyl salicylate, cinnamaldehyde, eugenol, 3-1-menthoxypropyl Single flavors such as alkane-1,2-diol, thymol, linalool, linalool acetate, limonene, menthone, menthyl acetate, N-substituted-p-menthane-3-carboxamide, pine terpenes, octanal, citral, pulegone, carvyl acetate, anisaldehyde, ethyl acetate, ethyl butyrate, allyl cyclohexane propionate, methyl anthranilate, ethyl methyl phenyl glycidate, vanillin, undecalactone, hexanal, butanol, isopentanol, hexenol, dimethyl sulfide, methylcyclopentenolone, furfural, trimethylpyrazine, ethyl lactate, methyl lactate, ethyl thioacetate, and blended flavors such as strawberry, apple, banana, pineapple, grape, mango, butter, milk, mixed fruit, and tropical fruit are used in the oral composition. Known flavor raw materials are not limited to the flavors described in the examples.

[0087] The blending amount of the fragrance is not particularly limited, but the fragrance raw materials described above are preferably used at 0.000001 to 1% in the composition, and the fragrance for aromatization using the fragrance raw materials described above are preferably used at 0.1 to 2% in the composition.

[0088] Optional active ingredients include nonionic bactericides such as isopropylmethylphenol, cationic bactericides such as cetylpyridinium chloride, anti-inflammatory agents such as tranexamic acid, ε-aminocaproic acid, and allantoin, enzymes such as dextranase, fluorine-containing compounds such as sodium fluoride and sodium monofluorophosphate, water-soluble phosphate compounds, sodium chloride, ascorbic acid, tocopherol acetate, plant extracts, anti-tartar agents, and anti-tartar agents. The active ingredients can be mixed in effective amounts within the range that does not hinder the effects of the present invention.

[0089] [Example]

[0090] The present invention will be described in detail below with reference to Examples and Comparative Examples, but the present invention is not limited to the following Examples. In the following examples, % means mass % unless otherwise specified.

[0091] [Examples, Comparative Examples]

[0092] The dentifrice compositions of the compositions shown in Tables 1 to 5 were prepared by a conventional method, filled into a laminated tube container, and used as a test dentifrice composition. The sensory hypersensitivity suppressing effect of the test dentifrice composition was evaluated by the following method. For the dentifrice composition having the composition shown in Table 1, the degree of odorlessness was also evaluated by the following method. In addition, the foaming of the dentifrice composition having the composition shown in Tables 2 to 5 during brushing was also evaluated by the following method. These results are comprehensively recorded in each table.

[0093] In addition, the toothpaste compositions shown in Tables 2 to 4 all had a odor-free degree of 2.5 or more as evaluated by the following method, indicating a good odor.

[0094] (1) Evaluation method of hyperesthesia suppression effect

[0095] The evaluation was conducted by conducting a sensory test using 10 panelists who felt a stinging sensation in their teeth when putting cold water in their mouths as subjects.

[0096] Extrusion test dentifrice composition, take 1 cm on the fingertips, print directly on the teeth with tingling, brush teeth for 3 minutes in the same way as usual, then immediately put cold water into the mouth, and judge the tingling of the teeth at this time according to the following scoring criteria.

[0097] <Evaluation Criteria>

[0098] 5 points: After brushing your teeth, when you put cold water in your mouth, your teeth don't hurt at all

[0099] 4 points: After brushing your teeth, your teeth do not hurt when you put cold water in your mouth

[0100] 3 points: After brushing your teeth, when you put cold water in your mouth, your teeth hardly feel any pain, which is considered a good level of pain.

[0101] 2 points: After brushing your teeth, your teeth sting when you put cold water into your mouth

[0102] 1 point: After brushing your teeth, when you put cold water into your mouth, your teeth feel a sharp pain.

[0103] The average score of 10 people was calculated for evaluation. If the average score of 10 people was less than 3.0, the rapidity of the hyperesthesia suppressive effect was judged to be low, 3.0 or more and less than 4.0, the rapidity of the hyperesthesia suppressive effect was judged to be excellent, and 4.0 or more, the rapidity of the hyperesthesia suppressive effect was judged to be even more excellent.

[0104] (2) Evaluation method of foaming during toothbrushing

[0105] Evaluation was performed by a sensory test using 10 expert panelists as subjects.

[0106] The test dentifrice composition was squeezed out and placed on a toothbrush to a depth of about 1.5 cm, and used in a normal toothbrushing method for about 1 week (twice a day). The foaming in the oral cavity during toothbrushing was evaluated according to the following scoring criteria.

[0107] <Evaluation Criteria>

[0108] 4 points: The foaming amount is very sufficient

[0109] 3 points: moderate foaming

[0110] 2 points: Little foaming

[0111] 1 point: Almost no bubbles

[0112] The average score of 10 people was calculated for evaluation. If the average score of 10 people was less than 2.5 points, the foaming was judged to be insufficient, 2.5 or more and less than 3.0 points, the foaming was judged to be good, and 3.0 points or more, the foaming was judged to be good.

[0113] (3) Evaluation method of odor (odorlessness)

[0114] Evaluation was performed through a sensory test using 10 expert panelists as subjects.

[0115] The test dentifrice composition was squeezed out and placed on a toothbrush to a depth of about 1.5 cm, and the toothbrush was used in a normal way to brush teeth. The degree of odorlessness felt during toothbrush brushing was evaluated according to the following scoring criteria.

[0116] <Evaluation Criteria>

[0117] 4 points: No odor at all

[0118] 3 points: Almost no odor

[0119] 2 points: Slightly smelly

[0120] 1 point: There is a strange smell

[0121] The average score of 10 people was calculated and evaluated. If the average score of 10 people was less than 2.5 points, the smell (no odor) was judged to be poor, 2.5 or more and less than 3.0 points, the smell (no odor) was judged to be good, and 3.0 points or more, the smell (no odor) was judged to be even better.

[0122] The details of the raw materials used are as follows.

[0123] (A) Ingredients:

[0124] Sodium polyacrylate (Mw: 1,000): linear, manufactured by Polyscience;

[0125] Sodium polyacrylate (Mw: 6,000): linear, manufactured by Toagosei Co., Ltd., JURYMER AC-10NP;

[0126] Sodium polyacrylate (Mw: 9,000): linear, manufactured by Polyscience;

[0127] Sodium polyacrylate (Mw: 20,000): linear, manufactured by Toagosei Co., Ltd., Aron A-20UN;

[0128] Sodium polyacrylate (Mw: 300,000, comparative product): cross-linked type, manufactured by Polyscience;

[0129] (B) Ingredients:

[0130] Potassium nitrate: manufactured by Otsuka Chemical Co., Ltd.;

[0131] Potassium acetate: manufactured by Yoneyama Chemical Industry Co., Ltd.

[0132] Potassium chloride: manufactured by Otsuka Chemical Co., Ltd.

[0133] Aluminum lactate: manufactured by Musashino Chemical Research Institute Co., Ltd.

[0134] Aluminum chloride: manufactured by Junsei Chemical Co., Ltd.

[0135] (C) Ingredients:

[0136] Sodium lauryl sulfate: manufactured by BASF Corporation, Texapon OC-P.

[0137] [Table 1]

[0138]

[0139] [Table 2]

[0140]

[0141] [Table 3]

[0142]

[0143] [Table 4]

[0144]

[0145] [Table 5]

[0146]

Claims

1. An oral composition comprising: (A) a polyacrylic acid salt having a weight average molecular weight of 1,000 or more and 20,000 or less, (B) at least one selected from the group consisting of potassium nitrate, potassium acetate, potassium chloride, aluminum lactate and aluminum chloride, and (C) alkyl sulfates, (C) the alkyl sulfate is at least one selected from sodium lauryl sulfate and sodium myristyl sulfate, The content of component (A) is 0.01 to 1% by mass, the content of component (B) is 1 to 10% by mass, and the content of component (C) is 0.1 to 2% by mass. The mass ratio of (A) / (B) is 0.005~0.2, and the mass ratio of (B) / (C) is 1~6. 2 . The oral composition according to claim 1 , wherein the component (B) is at least one selected from potassium nitrate and aluminum lactate. 3 . The oral composition according to claim 1 , wherein the component (A) is a polyacrylic acid salt having a weight average molecular weight of 6,000 to 9,000. The oral composition according to claim 1 , wherein the salt of the component (A) is an alkali metal salt or an ammonium salt. The oral composition according to claim 1 or 2, which is a dentifrice composition. The oral composition according to claim 1 or 2, which is for suppressing hyperesthesia.

Images